Page last updated: 2024-09-03

imatinib mesylate and Experimental Leukemia

imatinib mesylate has been researched along with Experimental Leukemia in 20 studies

Research

Studies (20)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	2 (10.00)	18.2507
2000's	9 (45.00)	29.6817
2010's	9 (45.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Du, X; Jin, Y; Li, J; Li, Y; Liu, C; Lu, Y; Nie, D; Pan, J; Zhou, J	1
Bazarbachi, A; El Eit, R; Itani, AR; Jabbour, M; Mahon, FX; Nasr, R; Nassar, F; Rasbieh, N; Santina, A; Zaatari, G	1
Brehm, MA; Green, MR; Hutchinson, L; Li, S; Ma, L; Ou, J; Pak, ML; Shan, Y; St Louis, P; Yu, J; Zhu, LJ	1
Bolton-Gillespie, E; Cerny-Reiterer, S; Dasgupta, Y; Gornicka, B; Hantschel, O; Hoser, G; Kantekure, K; Koptyra, M; Müschen, M; Nieborowska-Skorska, M; Richardson, C; Roy, D; Skorski, T; Stoklosa, T; Valent, P; van der Kuip, H; Wasik, MA	1
Bullinger, L; Chen, J; Fröhling, S; Gilliland, DG; Golub, TR; Gu, TL; Lee, BH; Monti, S; Tam, WF; Wang, A	1
Cools, J; De Keersmaecker, K; El Chaar, T; Ferrando, AA; Graux, C; Haferlach, T; Kleppe, M; Lahortiga, I; Langerak, AW; Meijerink, JP; Mentens, N; Sigaux, F; Soulier, J; Van Roosbroeck, K; Vandenberghe, P; Wlodarska, I	1
Adamia, S; Barrett, R; Choi, HG; Deng, X; Gray, N; Griffin, JD; Kung, AL; Moreno, D; Ray, A; Weisberg, E	1
Fu, L; Lou, L; Luo, H; Quan, H; Xie, C; Xu, Y	1
Gosden, RG; Melo, JV; Nijmeijer, BA; Schultheis, B; Yin, H	1
Chuah, C	1
Ilaria, R	1
Brain, J; Laneuville, P; Saksena, A	1
Groffen, J; Heisterkamp, N; Mishra, S; Zhang, B	1
Chen, L; Fei, XH; Gao, L; Qiu, HY; Wang, JM; Zhou, H	1
Boggon, TJ; Crispino, J; Deininger, MW; Druker, BJ; Eide, CA; Gilliland, DG; Goss, VL; Gu, TL; Heinrich, MC; Lee, KA; Loriaux, M; McGreevey, L; Mercher, T; Moore, SA; Nardone, J; O'Hare, T; Polakiewicz, RD; Stoffregen, EP; Tyner, JW; Walters, DK; Wong, MJ	1
Cools, J; Cortes, J; Garcia-Manero, G; Gilliland, DG; Kantarjian, H; Lee, F; Lennon, PA; Manshouri, T; Quintás-Cardama, A; Tong, W; Vega, F	1
Akahane, D; Nunoda, K; Ohyashiki, K; Okabe, S; Tauchi, T	1
Sausville, EA	1
Buchdunger, E; Cleris, L; Formelli, F; Gambacorti-Passerini, C; Giardini, R; le Coutre, P; Marchesi, E; Mologni, L	1
Ilaria, RL; Wolff, NC	1

Other Studies

20 other study(ies) available for imatinib mesylate and Experimental Leukemia

Article	Year
Antitumor Effects of Blocking Protein Neddylation in T315I-BCR-ABL Leukemia Cells and Leukemia Stem Cells. Cancer research, 2018, 03-15, Volume: 78, Issue:6 Topics: Animals; Antigens, CD34; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cyclopentanes; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Experimental; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Mice, Inbred C57BL; Molecular Targeted Therapy; Neoplastic Stem Cells; Point Mutation; Pyrimidines; Ubiquitin-Activating Enzymes	2018
Antitumor efficacy of arsenic/interferon in preclinical models of chronic myeloid leukemia resistant to tyrosine kinase inhibitors. Cancer, 2019, 08-15, Volume: 125, Issue:16 Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Arsenic Trioxide; Autophagy; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Hedgehog Proteins; Humans; Imatinib Mesylate; Interferon-alpha; Leukemia, Experimental; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mice, Inbred BALB C; Mice, Transgenic; Protein Kinase Inhibitors	2019
Prosurvival kinase PIM2 is a therapeutic target for eradication of chronic myeloid leukemia stem cells. Proceedings of the National Academy of Sciences of the United States of America, 2019, 05-21, Volume: 116, Issue:21 Topics: Animals; bcl-Associated Death Protein; Biphenyl Compounds; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Experimental; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mice; Molecular Targeted Therapy; Neoplastic Stem Cells; Phosphorylation; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; STAT Transcription Factors; Thiazolidines	2019
Normal ABL1 is a tumor suppressor and therapeutic target in human and mouse leukemias expressing oncogenic ABL1 kinases. Blood, 2016, 04-28, Volume: 127, Issue:17 Topics: Animals; Antineoplastic Agents; Apoptosis; Blast Crisis; Cell Division; Cell Line, Tumor; Cytostatic Agents; Gene Expression Regulation, Leukemic; Genes, abl; Genes, Tumor Suppressor; Genomic Instability; Humans; Imatinib Mesylate; Imidazoles; Leukemia, Experimental; Leukemia, Myeloid, Chronic-Phase; Mice; Mice, Inbred NOD; Mice, SCID; Neoplasm Proteins; Neoplastic Stem Cells; Oncogene Proteins v-abl; Oncogene Proteins, Fusion; Oxidative Stress; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-abl; Pyridazines; Tumor Suppressor Proteins	2016
Id1 is a common downstream target of oncogenic tyrosine kinases in leukemic cells. Blood, 2008, Sep-01, Volume: 112, Issue:5 Topics: Animals; Antineoplastic Agents; Apoptosis; Benzamides; Cell Line, Tumor; Cell Transformation, Neoplastic; Gene Expression; HL-60 Cells; Humans; Imatinib Mesylate; Inhibitor of Differentiation Protein 1; K562 Cells; Leukemia; Leukemia, Experimental; Mice; Oncogenes; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Quinazolines; RNA, Small Interfering; Signal Transduction	2008
Deletion of the protein tyrosine phosphatase gene PTPN2 in T-cell acute lymphoblastic leukemia. Nature genetics, 2010, Volume: 42, Issue:6 Topics: Animals; Benzamides; Cell Line; Cell Line, Tumor; Chemokine CCL1; Gene Deletion; Gene Knockdown Techniques; Homeodomain Proteins; Humans; Imatinib Mesylate; Interleukin-2; Interleukin-7; Leukemia, Experimental; Mice; Piperazines; Precursor T-Cell Lymphoblastic Leukemia-Lymphoma; Protein Tyrosine Phosphatase, Non-Receptor Type 2; Proto-Oncogene Proteins; Pyrimidines	2010
Beneficial effects of combining a type II ATP competitive inhibitor with an allosteric competitive inhibitor of BCR-ABL for the treatment of imatinib-sensitive and imatinib-resistant CML. Leukemia, 2010, Volume: 24, Issue:7 Topics: Adenosine Triphosphate; Animals; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Cells, Cultured; Drug Resistance, Neoplasm; Drug Synergism; Fusion Proteins, bcr-abl; Imatinib Mesylate; Leukemia, Experimental; Mice; Piperazines; Precursor Cells, B-Lymphoid; Protein Kinase Inhibitors; Pyrimidines; Thiazoles; Xenograft Model Antitumor Assays	2010
HH-GV-678, a novel selective inhibitor of Bcr-Abl, outperforms imatinib and effectively overrides imatinib resistance. Leukemia, 2010, Volume: 24, Issue:10 Topics: Aminopyridines; Animals; Antineoplastic Agents; Apoptosis; Benzamides; Blotting, Western; Cell Proliferation; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Experimental; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mice; Mice, Nude; Phosphorylation; Piperazines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Pyridines; Pyrimidines; Receptor, Platelet-Derived Growth Factor beta; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Survival Rate; Tumor Cells, Cultured; Xenograft Model Antitumor Assays	2010
Imatinib mesylate at therapeutic doses has no impact on folliculogenesis or spermatogenesis in a leukaemic mouse model. Leukemia research, 2012, Volume: 36, Issue:3 Topics: Animals; Benzamides; Disease Models, Animal; Dose-Response Relationship, Drug; Female; Imatinib Mesylate; Leukemia, Experimental; Male; Mice; Mice, Inbred C3H; Ovarian Follicle; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Spermatogenesis	2012
Imatinib does not impair gonadal function. Leukemia research, 2012, Volume: 36, Issue:3 Topics: Animals; Benzamides; Disease Models, Animal; Female; Imatinib Mesylate; Leukemia, Experimental; Male; Ovarian Follicle; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Spermatogenesis	2012
Bcr/Abl, leukemogenesis, and genomic instability: a complex partnership. Leukemia research, 2002, Volume: 26, Issue:11 Topics: Animals; Benzamides; Chromosome Aberrations; Enzyme Inhibitors; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Kidney; Leukemia, Experimental; Mice; Piperazines; Point Mutation; Protein-Tyrosine Kinases; Pyrimidines; Spleen	2002
The kinase inhibitor STI571 reverses the Bcr-Abl induced point mutation frequencies observed in pre-leukemic P190(Bcr-Abl) transgenic mice. Leukemia research, 2002, Volume: 26, Issue:11 Topics: Animals; Benzamides; Chromosome Aberrations; Enzyme Inhibitors; Fusion Proteins, bcr-abl; Gene Expression Regulation, Leukemic; Homozygote; Imatinib Mesylate; Kidney; Leukemia, Experimental; Mice; Mice, Inbred C57BL; Mice, Transgenic; Mutagenesis; Piperazines; Point Mutation; Proto-Oncogene Proteins c-abl; Pyrimidines; Remission Induction; Spleen	2002
A farnesyltransferase inhibitor increases survival of mice with very advanced stage acute lymphoblastic leukemia/lymphoma caused by P190 Bcr/Abl. Leukemia, 2004, Volume: 18, Issue:1 Topics: Administration, Oral; Alkyl and Aryl Transferases; Animals; Antineoplastic Agents; Benzamides; Disease Models, Animal; Farnesyltranstransferase; Female; Fusion Proteins, bcr-abl; Imatinib Mesylate; Leukemia, Experimental; Lymphoma; Mice; Mice, Inbred C57BL; Mice, Inbred CBA; Mice, Nude; Mice, Transgenic; Piperazines; Piperidines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein-Tyrosine Kinases; Pyridines; Pyrimidines; Survival Rate; Tumor Cells, Cultured	2004
STI571 combined with vincristine greatly suppressed the tumor formation of multidrug-resistant K562 cells in a human-nude mice xenograft model. Chinese medical journal, 2006, Jun-05, Volume: 119, Issue:11 Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 1; Benzamides; Cell Proliferation; Daunorubicin; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; K562 Cells; Leukemia, Experimental; Mice; Mice, Nude; Neoplasm Transplantation; Piperazines; Pyrimidines; Transplantation, Heterologous; Vincristine	2006
Activating alleles of JAK3 in acute megakaryoblastic leukemia. Cancer cell, 2006, Volume: 10, Issue:1 Topics: Alleles; Animals; Apoptosis; Benzamides; Cell Line, Tumor; Cell Proliferation; Cell Survival; Humans; Imatinib Mesylate; Janus Kinase 2; Janus Kinase 3; K562 Cells; Leukemia, Experimental; Leukemia, Megakaryoblastic, Acute; Mice; Mice, Inbred C57BL; Models, Molecular; Mutant Proteins; Phosphorylation; Piperazines; Protein Kinase Inhibitors; Protein Structure, Tertiary; Protein-Tyrosine Kinases; Proto-Oncogene Proteins; Pyrimidines; RNA, Small Interfering; TYK2 Kinase	2006
Activity of tyrosine kinase inhibitors against human NUP214-ABL1-positive T cell malignancies. Leukemia, 2008, Volume: 22, Issue:6 Topics: Adaptor Proteins, Signal Transducing; Adult; Animals; Apoptosis; Benzamides; Blotting, Western; Cell Cycle; Cell Proliferation; Cell Survival; Dasatinib; Female; Humans; Imatinib Mesylate; In Situ Hybridization, Fluorescence; Leukemia-Lymphoma, Adult T-Cell; Leukemia, Experimental; Male; Mice; Mice, Inbred NOD; Mice, SCID; Nuclear Proteins; Oncogene Proteins, Fusion; Phosphorylation; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Reverse Transcriptase Polymerase Chain Reaction; STAT5 Transcription Factor; Thiazoles; Tumor Cells, Cultured	2008
Activity of a novel Aurora kinase inhibitor against the T315I mutant form of BCR-ABL: in vitro and in vivo studies. Cancer science, 2008, Volume: 99, Issue:6 Topics: Animals; Antineoplastic Agents; Apoptosis; Aurora Kinases; Benzamides; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Colony-Forming Units Assay; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Drug Therapy, Combination; Enzyme Inhibitors; Female; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Immunoblotting; Immunoprecipitation; K562 Cells; Leukemia, Experimental; Mice; Mice, Nude; Phosphorylation; Piperazines; Protein Serine-Threonine Kinases; Protein-Tyrosine Kinases; Pyrimidines; Survival Rate	2008
A Bcr/Abl kinase antagonist for chronic myelogenous leukemia: a promising path for progress emerges. Journal of the National Cancer Institute, 1999, Jan-20, Volume: 91, Issue:2 Topics: Animals; Antineoplastic Agents; Benzamides; Enzyme Inhibitors; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Experimental; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Signal Transduction	1999
In vivo eradication of human BCR/ABL-positive leukemia cells with an ABL kinase inhibitor. Journal of the National Cancer Institute, 1999, Jan-20, Volume: 91, Issue:2 Topics: Animals; Antineoplastic Agents; Benzamides; Enzyme Inhibitors; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Experimental; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mice; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Signal Transduction; Tumor Cells, Cultured	1999
Establishment of a murine model for therapy-treated chronic myelogenous leukemia using the tyrosine kinase inhibitor STI571. Blood, 2001, Nov-01, Volume: 98, Issue:9 Topics: Animals; Antineoplastic Agents; Benzamides; Bone Marrow Cells; Bone Marrow Transplantation; Disease Models, Animal; DNA-Binding Proteins; Fusion Proteins, bcr-abl; Imatinib Mesylate; Immediate-Early Proteins; Leukemia, Experimental; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukocyte Count; Mice; Mice, Inbred BALB C; Milk Proteins; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Retroviridae; RNA, Messenger; Spleen; STAT5 Transcription Factor; Suppressor of Cytokine Signaling Proteins; Survival Rate; Trans-Activators; Transduction, Genetic	2001